CCI
RIGL icon

Columbus Circle Investors’s Rigel Pharmaceuticals RIGL Stock Holding History

Columbus Circle Investors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,117
Closed -$730K – 296
2014
Q2 		$730K Buy
+20,117
New +$684K 0.01% 266

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Columbus Circle Investors's RIGL Position: Q3 2014 in Review

Columbus Circle Investors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2014, closing a stake of 20,117 shares — an estimated $730K sold.

Columbus Circle Investors first reported a position in RIGL in Q2 2014 and held it in 1 quarter. The position peaked at $730K in Q2 2014. 104 funds tracked by Wall St. Rank hold RIGL as of Q3 2014.

  • Columbus Circle Investors reported no remaining Rigel Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Columbus Circle Investors sold 20,117 Rigel Pharmaceuticals shares in Q3 2014, an estimated $730K.
  • Columbus Circle Investors first reported a position in Rigel Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Columbus Circle Investors's Rigel Pharmaceuticals position peaked at $730K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2014.

Based on Columbus Circle Investors's 13F filing for Q3 2014, filed 5 Nov 2014.